• Glutamine Metabolism in Hepatic Stellate Cells

  2026-08-09

  The 2022 Cell Death and Disease study identifies SIRT4-mediated control of glutamate dehydrogenase as a metabolic brake on hepatic stellate cell activation and liver fibrosis. Its combination of pharmacological, genetic, cellular, and in vivo evidence supports glutamine catabolism as a mechanistically grounded target for antifibrotic research.

• IWR-1-endo: From Pathway Blockade to Cell States

  2026-08-08

  IWR-1-endo is a potent Wnt signaling inhibitor for dissecting β-catenin-dependent biology. This article connects its Axin-complex mechanism with cell-state-resolved assay design inspired by large-scale single-nucleus profiling in atrial fibrillation research.

• Toremifene in Breast Cancer: 20 Years of Evidence

  2026-08-07

  This review synthesizes two decades of clinical and pharmacologic evidence on toremifene, positioning it as an effective endocrine option for selected postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is a clinically useful comparison of toremifene with tamoxifen and aromatase inhibitors, while highlighting receptor biology, CYP2D6-related metabolism, bone effects, lipid effects, and treatment tolerability.

• Prochlorperazine as a Dopamine D2 Receptor Antagonist in Res

  2026-08-07

  Prochlorperazine’s multi-receptor antagonism and robust in vitro efficacy make it a versatile tool for melanoma research and antiemetic assay development. Recent clinical trials underscore its translational potential, opening new avenues for both mechanistic studies and applied workflows.

• SMYD2 Inhibition Prevents Cisplatin-Induced Renal Fibrosis

  2026-08-06

  The referenced study demonstrates that pharmacological inhibition of SMYD2 with agents such as LLY-507 protects against cisplatin-induced renal fibrosis and inflammation in preclinical models. This work identifies SMYD2 as a regulator of chronic kidney disease progression, highlighting new avenues for targeted epigenetic therapy.

• Tat-Induced H3K27me3 and EZH2 Drive HIV Latency in Astrocyte

  2026-08-06

  This study demonstrates that HIV-1 Tat expression promotes histone H3K27 trimethylation via upregulation of EZH2 and MeCP2, thereby contributing to the establishment and maintenance of HIV latency in astrocytes. Pharmacological inhibition of EZH2 with GSK126 reactivates latent HIV, providing mechanistic insight and a potential epigenetic intervention point.

• BIRC2 and BIRC3 Regulation by Cytokines and Glucocorticoids

  2026-08-05

  This study delineates how inflammatory cytokines and glucocorticoids differentially regulate BIRC2 and BIRC3 in pulmonary epithelial cells. The findings clarify the timing, mechanisms, and signaling dependencies of these anti-apoptotic proteins, supporting new approaches to dissecting epithelial cell survival and immune responses.

• Busulfan as a DNA Alkylating Agent: Experimental Workflows &

  2026-08-05

  Busulfan stands out as a DNA alkylating agent for inducing cellular senescence and germ cell depletion, enabling precision modeling in both cellular and animal systems. This article translates the latest genetic tracing breakthroughs and protocol optimizations into actionable guidance for researchers leveraging Busulfan in experimental workflows.

• Valemetostat (DS-3201): Protocol-Driven Advances in Lymphoma

  2026-08-04

  Valemetostat (DS-3201) stands out as a precision dual EZH1/EZH2 inhibitor, enabling highly reproducible, mutation-targeted workflows in lymphoma research and immuno-oncology. This article translates recent breakthroughs into actionable protocols, troubleshooting guidance, and comparative advantage for maximizing epigenetic therapy and experimental immunotherapy outcomes.

• Haloprogin: Advanced Insights into Broad-Spectrum Antimicrob

  2026-08-04

  Explore the multifaceted antimicrobial activities of Haloprogin, including its unique molecular action and practical implications for research on dermatophytes, Candida, and Gram-positive bacteria. This article delivers a critical analysis distinct from existing content, with detailed assay guidance and new perspectives on experimental design.

• Redefining mRNA Translation: EZ Cap EGFP mRNA 5-moUTP in Act

  2026-08-03

  This thought-leadership article explores how EZ Cap™ EGFP mRNA (5-moUTP) transforms the translational research landscape by integrating advanced mRNA engineering with mechanistic immune evasion. Bridging biological rationale, workflow innovation, and strategic foresight, it contextualizes APExBIO’s solution amid evolving challenges in mRNA delivery, immune memory, and in vivo imaging. With evidence from recent peer-reviewed studies and a critical look at the competitive field, it offers actionable guidance for researchers navigating next-generation mRNA-based assays and therapeutic models.

• Screening MMV Pandemic Box for Potent Antifungals Against Ca

  2026-08-03

  This study systematically evaluated MMV Pandemic Response Box compounds against multidrug-resistant bacterial and fungal clinical isolates, identifying several candidates with notable activity against Candida species. The work highlights the need for targeted antifungal strategies and provides a framework for preclinical compound prioritization.

• Anlotinib Hydrochloride: Engineered for Translational Angiog

  2026-08-02

  A thought-leadership article for translational researchers, exploring how Anlotinib hydrochloride redefines anti-angiogenic study protocols by uniting mechanistic specificity with strategic workflow guidance. Drawing on key literature and competitive data, the piece bridges core biological insights with practical assay design, positioning APExBIO’s Anlotinib as a next-generation research standard.

• SERCA2 Dysfunction Drives Inflammation via PPARγ/PGC1α/Nrf2

  2026-08-01

  This study uncovers how SERCA2 dysfunction in pulmonary artery smooth muscle cells initiates inflammation and vascular remodeling by suppressing the PPARγ/PGC1α/Nrf2 axis. The findings identify new molecular targets and provide actionable insights for oxidative stress and pulmonary hypertension research.

• Translating NAMPT Inhibition: FK866 (APO866) in AML Research

  2026-07-31

  This thought-leadership article dissects the mechanistic and translational frontiers of FK866 (APO866), a potent non-competitive NAMPT inhibitor, spotlighting its pivotal role in acute myeloid leukemia (AML) research. We bridge fundamental biological insight with actionable protocol guidance, critically examine the evolving landscape of NAD metabolism targeting, and chart a visionary path for translational researchers seeking to weaponize metabolic vulnerabilities in hematologic malignancies.

7805 records 5/521 page Previous Next 12345 下5页 Last page